Cambridge Healthtech Institute第三屆

Oligonucleotide Discovery and Delivery

( 低聚核苷酸療法的創藥與運輸 )

適體、反義與RNA療法之開發與運輸技術的進步

2018年3月26-28日 | Boston Marriott Cambridge | 馬薩諸塞州劍橋

低聚核苷酸療法長久以來被認為是形成第三大藥物發展平台的存在,尤其專注於藉由標的RNA轉錄產物或基因體自身來調節基因表現方面。使用核酸作為治療手段的關鍵特徵在於進入小分子藥物及生物製劑無法對應的「無法藥物化」領域,讓藥物開發人員得以開發目前有所受限或缺乏治療選項的疾病領域。可惜由於第一代及第二代分子的效力與安全性方面浮現問題,目前為止低聚核苷酸療法仍未對藥物開發界造成劇烈影響。然而隨著核酸藥物與運送技術領域研究的進步,使用化學修飾與結合技術提升穩定性、生體可用性、特異性、效力,開拓了通往新世代低聚核苷酸療法的道路。有了這些進展,以及穩健發展的環境、數項可能獲得核可的晚期臨床試驗產品,再度提高了對低聚核苷酸療法開發的關心度。

有了過去的顯著成果,CHI很榮幸地將在3月26日∼28日舉辦第三屆低聚核苷酸與胜肽療法年會。與會者可在本會議中與從事低聚核苷酸療法發現與開發相關工作的研究者共聚一堂,針對核酸合成、藥物化學、運輸等領域中,技術面及研究面的進步、臨床前及臨床研究成果等主題進行熱烈討論。

Who should attend: Executives, Directors, Managers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oligonucleotide Therapeutics, Immunotherapy, Gene Therapy, Gene Editing and Rare Diseases.

Topics will include, but are not limited to:

Therapeutic Oligonucleotides - Coverage Includes:

  • Antisense single-stranded DNA/RNA oligonucleotides (ASOs)
  • siRNA
  • mRNA
  • ncRNA
  • Aptamers

Part 1: Therapeutic Oligonucleotide Discovery and Development

  • Oligonucleotides for:
    • RNA modulation
    • Antivirals
    • Splicing modulation and exon skipping
    • DNAi
    • Gene editing
      • CRISPR/Cas9
  • Oligonucleotide Synthesis and Chemistry
  • Aptamer Therapeutics
  • Preclinical and Clinical Studies
  • Combination Strategies

Part 2: Delivery

  • Chemical Modifications and Conjugation
    • Improving stability, bioavailability, specificity and potency
  • Improved Oligonucleotide Delivery Methods
    • Nanomaterial-based delivery
    • Non-viral delivery systems
    • Small molecule based delivery
    • Delivery methods for non-hepatic targets
      • Blood-brain barrier
    • Delivery of large nucleic acids

Part 3: Oligonucleotides for Cancer Immunotherapy

  • RNA-Based Vaccines
    • Chemical modifications
    • Immuno-stimulatory adjuvants and co-stimulatory molecules
      • Toll-like receptor agonists
      • Targeting the STING pathway
    • Delivery of RNA vaccines
    • Non-viral delivery strategies
  • Dendritic Cell Vaccines
  • Preclinical and Clinical Combination Studies with Checkpoint Inhibitors
  • Novel Agents Inducing Immune Response
  • Novel Targets for Immunotherapy Development

The deadline for submission is September 15, 2017.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

* 活動內容有可能不事先告知作更動及調整。